Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):12971-12977. doi: 10.26355/eurrev_202012_24201.
The incidence of obesity and other metabolic-related diseases has been gradually increasing. Multiple genetic as well as environmental factors play a significant role in the pathogenesis of these entities. Currently, the involvement of gut microbiota in metabolic processes has been acknowledged. This paper focuses on obesity, type 2 diabetes, and nonalcoholic fatty liver disease regarding their link with microbiome structure and its function.
We analyzed literature available in PubMed, Embase, and Google Scholar databases regarding a linkage of metabolic-associated diseases and gut microbiota RESULTS: Gut microbiota plays a significant role in host metabolism. Depending on its composition; however, it may contribute to the development of metabolic-associated diseases. In this context, not only composition of gut microbiota is important, but also its activity. Short-chain fatty acids or lipopolysaccharides are crucial metabolites involved in maintaining metabolic balance.
Gut microbiota malfunctions might potentially induce obesity, type 2 diabetes, and nonalcoholic fatty liver disease.
肥胖症和其他代谢相关疾病的发病率逐渐上升。多种遗传和环境因素在这些疾病的发病机制中起重要作用。目前,肠道微生物群在代谢过程中的作用已得到认可。本文主要关注肥胖症、2 型糖尿病和非酒精性脂肪性肝病与微生物组结构及其功能的关系。
我们分析了 PubMed、Embase 和 Google Scholar 数据库中关于代谢相关疾病和肠道微生物群相关性的文献。
肠道微生物群在宿主代谢中起重要作用。然而,根据其组成,它可能导致代谢相关疾病的发生。在这种情况下,不仅肠道微生物群的组成很重要,其活性也很重要。短链脂肪酸或脂多糖是参与维持代谢平衡的关键代谢物。
肠道微生物群功能障碍可能潜在地导致肥胖症、2 型糖尿病和非酒精性脂肪性肝病。